When travel sells off with no company news, crude is hitting demand next.
Business
A melanoma Phase 3 win and an FDA-approved flu vaccine give Moderna its first credible platform since...
Companies are cutting payrolls and backfilling with project-based experts. The bull case for this shift is real....
Russia’s diesel export ban runs to Sept. 30. ULSD cracks stay the trade, and complex refiners are...
With leverage at 3.8x EBITDA and a payout ratio near 85%, the committee asks if the income...
Freeport restarts this week, EU storage is still below normal, and the Russian LNG cutoff clock is...
HBM is sold out. DRAM is tightening. These four companies are not equally priced for what comes...
A record Q2 beat rate has raised the bar so high that even a strong H2 may...
APT prices have surged since early 2026. Almonty is ramping Sangdong and just expanded a 21-year offtake...
A $626 million operating loss, a $104 billion backlog, and a capex guide that just jumped again,...
